March 6, 2015—Genentech’s decision last fall to move its top-selling cancer drugs Avastin, Herceptin, and Rituxan into the specialty distribution channel has cost hospitals more than $300 million and disrupted patient care, a survey of more than 200 hospitals has found. Nearly two out of five hospitals (39 percent) surveyed said the change affects their risk of 340B program non-compliance.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)